Literature DB >> 24752056

Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.

Emmanouil Fokas1, Torsten Liersch2, Rainer Fietkau2, Werner Hohenberger2, Tim Beissbarth2, Clemens Hess2, Heinz Becker2, Michael Ghadimi2, Karl Mrak2, Susanne Merkel2, Hans-Rudolf Raab2, Rolf Sauer2, Christian Wittekind2, Claus Rödel2.   

Abstract

PURPOSE: We previously described the prognostic impact of tumor regression grading (TRG) on the outcome of patients with rectal carcinoma treated with preoperative chemoradiotherapy (CRT) in the CAO/ARO/AIO-94 trial. Here we report long-term results after a median follow-up of 132 months. PATIENTS AND METHODS: TRG after preoperative CRT was determined in 386 surgical specimens by the amount of viable tumor cells versus fibrosis, ranging from TRG 4 (no viable tumor cells) to TRG 0 (no signs of regression). Clinicopathologic parameters and TRG were correlated to the cumulative incidence of local recurrence, distant metastasis, and disease-free survival (DFS).
RESULTS: Ten-year cumulative incidence of distant metastasis and DFS were 10.5% and 89.5% for patients with TRG 4 (complete regression), 29.3% and 73.6% for TRG 2 and 3 (intermediate regression), and 39.6% and 63% for TRG 0 and 1 (poor regression), respectively (P = .005 and P = .008, respectively). On multivariable analysis, residual lymph node metastasis (ypN+) and TRG were the only independent prognostic factors for cumulative incidence of distant metastasis (P < .001 and P = .035, respectively) and DFS (P < .001 and P = .039, respectively), whereas local recurrence was significantly affected by ypN status (P < .001) and lymphatic invasion (P = .026).
CONCLUSION: Complete and intermediate tumor regressions were associated with improved long-term outcome in patients with rectal carcinoma after preoperative CRT independent of clinicopathologic parameters. This classification system needs to be prospectively tested in multiple data sets to validate its reproducibility in a wider setting.
© 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2014        PMID: 24752056     DOI: 10.1200/JCO.2013.54.3769

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  134 in total

1.  College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.

Authors:  Hai-Yang Chen; Li-Li Feng; Ming Li; Huai-Qiang Ju; Yi Ding; Mei Lan; Shu-Mei Song; Wei-Dong Han; Li Yu; Ming-Biao Wei; Xiao-Lin Pang; Fang He; Shuai Liu; Jian Zheng; Yan Ma; Chu-Yang Lin; Ping Lan; Mei-Jin Huang; Yi-Feng Zou; Zu-Li Yang; Ting Wang; Jin-Yi Lang; Guy R Orangio; Vitaliy Poylin; Jaffer A Ajani; Wei-Hu Wang; Xiang-Bo Wan
Journal:  Oncologist       Date:  2021-02-22

2.  Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses.

Authors:  Stephanie Nougaret; Hebert Alberto Vargas; Yulia Lakhman; Romain Sudre; Richard K G Do; Frederic Bibeau; David Azria; Eric Assenat; Nicolas Molinari; Marie-Ange Pierredon; Philippe Rouanet; Boris Guiu
Journal:  Radiology       Date:  2016-02-26       Impact factor: 11.105

3.  [Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].

Authors:  T Sprenger; H Rothe; T Beissbarth; L-C Conradi; A Kauffels; K Homayounfar; C L Behnes; C Rödel; T Liersch; M Ghadimi
Journal:  Chirurg       Date:  2016-07       Impact factor: 0.955

Review 4.  [Evidence-based surgery of rectal cancer].

Authors:  M Grade; H Flebbe; B M Ghadimi
Journal:  Chirurg       Date:  2019-05       Impact factor: 0.955

5.  Genomic predictor of complete response after chemoradiotherapy in rectal cancer.

Authors:  Gyoung Tae Noh; Nam Kyu Kim
Journal:  Ann Transl Med       Date:  2016-12

6.  Clinical significance of cellular and acellular mucin pools in rectal carcinoma following preoperative chemoradiotherapy.

Authors:  J A Cienfuegos; J Baixauli; F Rotellar; J Arredondo; J J Sola; L Arbea; C Pastor; J L Hernández-Lizoáin
Journal:  Clin Transl Oncol       Date:  2015-10-16       Impact factor: 3.405

Review 7.  Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.

Authors:  Rupert Langer; Karen Becker
Journal:  Virchows Arch       Date:  2017-09-16       Impact factor: 4.064

8.  MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.

Authors:  Natally Horvat; Harini Veeraraghavan; Monika Khan; Ivana Blazic; Junting Zheng; Marinela Capanu; Evis Sala; Julio Garcia-Aguilar; Marc J Gollub; Iva Petkovska
Journal:  Radiology       Date:  2018-03-07       Impact factor: 11.105

9.  A Modified Classification of Prognostic Factors Based on Pathological Stage and Tumor Regression Grade in Patients with Rectal Cancer Who Receive Preoperative Chemoradiotherapy.

Authors:  Toshiyuki Suzuki; Sotaro Sadahiro; Akira Tanaka; Kazutake Okada; Gota Saito; Hiroshi Miyakita; Takeshi Akiba; Hiroshi Yamamuro
Journal:  Oncology       Date:  2017-07-21       Impact factor: 2.935

10.  Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.

Authors:  Filippo Landi; Eloy Espín; Victor Rodrigues; Francesc Vallribera; Aleix Martinez; Cecile Charpy; Francesco Brunetti; Daniel Azoulay; Nicola de'Angelis
Journal:  Int J Colorectal Dis       Date:  2016-10-19       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.